Searchable abstracts of presentations at key conferences in endocrinology

ea0029p368 | Clinical case reports - Pituitary/Adrenal | ICEECE2012

Efficacy of tolvaptan treatment in a patient with syndrome of inappropriate antidiuresis (SIAD) after severe traumatic brain injury

Bondanelli M. , Malaspina A. , Montis A. , Ambrosio M. , Lavezzi S. , Basaglia N. , Zatelli M. , degli Uberti E.

Tolvaptan, an oral antagonist of the vasopressin V2 receptor, has been found to improve hyponatremia in patients with SIAD. We report the case of a 65-years-old male, who developed recurrent episodes of hyponatremia after severe traumatic brain injury, TBI, with polytrauma (CGS=8, decompressive craniectomy, spontaneous breathing by percutaneous tracheotomy). During hospitalization in intensive care unit he resumed alertness and received i.v. hypertonic saline infusion and oral...

ea0026p180 | Neuroendocrinology | ECE2011

Targeting PKC in human pancreatic neuroendocrine tumor cells

Mole D , Gagliano T , Gentilin E , Bondanelli M , Tagliati F , degli Uberti E , Zatelli M C

The currently curative therapy for pancreatic endocrine tumours (PET), accounting for <3% of pancreatic tumors, is complete surgical resection, which is achieved in the minority of cases. Most tumors are diagnosed in a late stage, especially in endocrine-inactive forms, indicating the need for further medical therapy. The serine–threonine protein kinase C (PKC) family plays central regulatory roles in several cellular processes, including cell proliferation. PKC signa...

ea0011p29 | Bone | ECE2006

Evaluation of bone markers and structure in subclinical Cushing’s syndrome

Monesi M , Ambrosio MR , Taroni S , Bondanelli M , Zatelli MC , degli Uberti EC

Overt hypercortisolism causes reduction in bone mass and density. The effects of subclinical Cushing’s syndrome (SCS) on bone markers and structure are still debated. We therefore studied 56 patients with adrenal incidentaloma: group A=35 (20 F 15 M, age 43–79, mean 64.6±1.5; BMI 29.9±0.9 kg/m2) without evidence of hypercortisolism, and group B=21 (10 F 11 M, age 51–76, mean 63.4±1.9, BMI 28.0±1.2 kg/m2) with SCS (i.e. w...

ea0011p462 | Endocrine tumours and neoplasia | ECE2006

Selective Cyclo-oxygenase 2 inhibitors revert chemoresistance In Medullary thyroid carcinoma by a mechanism mediated by P-gp and PGH2

Zatelli MC , Luchin A , pICCIN D , Tagliati F , Bottoni A , Vignali C , Bondanelli M , degli Uberti EC

Medullary thyroid carcinoma (MTC) is a malignant tumour deriving from parafollicular C cells, with a highly chemoresistant phenotype. Failure of medical therapy has been ascribed, at least in part, to multi drug resistance (MDR1) gene over-expression. MDR1 encodes for a transmembrane glycoprotein, P-gp, which hampers intracellular accumulation of cytotoxic drugs. It has been demonstrated that P-gp expression and function depend on cyclo-oxygenase 2 (COX-2) expression, which is...